Management of nausea and vomiting (N/V) following first-line (1L) zolbetuximab + chemotherapy treatment in claudin-18.2 (CLDN18.2)+, HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Analysis from the phase 3 SPOTLIGHT and GLOW studies
Shitara, Kohei, Pophale, Rupesh, Matsangou, Maria, Park, Jung Wook, Oh, Mok, Bhattacharya, Pranob P., Ranganath, Radhika
Published in Journal of clinical oncology (20.01.2024)
Published in Journal of clinical oncology (20.01.2024)
Get full text
Journal Article
Phase 2 trial of zolbetuximab in combination with mFOLFOX6 and nivolumab in patients with advanced or metastatic claudin 18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinomas
Shitara, Kohei, Yamaguchi, Kensei, Shoji, Hirokazu, Matsangou, Maria, Bhattacharya, Pranob P., Park, Jung Wook, Klempner, Samuel J
Published in Journal of clinical oncology (01.06.2023)
Published in Journal of clinical oncology (01.06.2023)
Get full text
Journal Article
Global prevalence of CLDN18.2 in patients with locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Biomarker analysis of two zolbetuximab phase 3 studies (SPOTLIGHT and GLOW)
Shitara, Kohei, Xu, Rui-Hua, Moran, Diarmuid Martin, Guerrero, Abraham, Li, Ran, Pavese, Janet, Matsangou, Maria, Bhattacharya, Pranob P., Ajani, Jaffer A., Shah, Manish A.
Published in Journal of clinical oncology (01.06.2023)
Published in Journal of clinical oncology (01.06.2023)
Get full text
Journal Article
Network meta-analysis of global trials of 1L therapies in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
Shah, Manish A., Shitara, Kohei, Lonardi, Sara, Chao, Yee, Yamaguchi, Kensei, Kukielka-Budny, Bozena, Ryu, Min-Hee, Ungureanu, Andrei, Oh, Mok, Chang, Lawrence, Yang, Hongbo, Chai, Xinglei, Bhattacharya, Pranob P., Matsangou, Maria, Ranganath, Radhika, Ajani, Jaffer A., Xu, Rui-Hua
Published in Journal of clinical oncology (20.01.2024)
Published in Journal of clinical oncology (20.01.2024)
Get full text
Journal Article
Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in first-line treatment of claudin 18.2–positive metastatic pancreatic cancer (mPC): Phase 2, open-label, randomized study
Park, Wungki, O'Reilly, Eileen Mary, Furuse, Junji, Li, Chung-Pin, Oh, Do-Youn, Garcia-Carbonero, Rocio, Roth, Gaël, Lee, Ho-Jin, Bhattacharya, Pranob P., Moran, Diarmuid Martin, Yang, Jianning, Kunieda, Futoshi
Published in Journal of clinical oncology (01.02.2023)
Published in Journal of clinical oncology (01.02.2023)
Get full text
Journal Article
Zolbetuximab + CAPOX in 1L claudin-18.2+ (CLDN18.2+)/HER2− locally advanced (LA) or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary phase 3 results from GLOW
Xu, Rui-hua, Shitara, Kohei, Ajani, Jaffer A., Bang, Yung-Jue, Enzinger, Peter C., Ilson, David H., Lordick, Florian, Van Cutsem, Eric, Gallego Plazas, Javier, Huang, Jing, Shen, Lin, Oh, Sang Cheul, Sunpaweravong, Patrapim, Soo Hoo, Hwoei Fen, Turk, Haci M., Park, Jung Wook, Moran, Diarmuid Martin, Bhattacharya, Pranob P., Arozullah, Ahsan, Shah, Manish A.
Published in Journal of clinical oncology (20.04.2023)
Published in Journal of clinical oncology (20.04.2023)
Get full text
Journal Article
Zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) withclaudin-18.2+ (CLDN18.2+) / HER2− locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary results from phase 3 SPOTLIGHT study
Shitara, Kohei, Lordick, Florian, Bang, Yung-Jue, Enzinger, Peter C., Ilson, David H., Shah, Manish A., Van Cutsem, Eric, Xu, Rui-hua, Aprile, Giuseppe, Xu, Jianming, Chao, Joseph, Pazo-Cid, Roberto, Kang, Yoon-Koo, Yang, Jianning, Moran, Diarmuid Martin, Bhattacharya, Pranob P., Arozullah, Ahsan, Wook Park, Jung, Ajani, Jaffer A.
Published in Journal of clinical oncology (01.02.2023)
Published in Journal of clinical oncology (01.02.2023)
Get full text
Journal Article